Mountain Valley MD: A Year of Progress and Growth Opportunities

Mountain Valley MD Holdings Inc. (MVMD), a Canadian biotechnology company, has provided a comprehensive business update for the 2024 fiscal year, highlighting significant advancements in its commercialization strategies across three core areas: nutraceuticals, agriculture, and husbandry animals/aquatic species. The company's progress is a testament to its commitment to innovation and global impact, as stated by Dennis Hancock, President & CEO of Mountain Valley MD.

Nutraceuticals: Quicksome™ Technology and Business Development Progress

MVMD's patented liposomal Quicksome™ technology has demonstrated remarkable potential in optimizing molecule delivery through sublingual nutraceutical applications. The technology's benefits include enhanced efficacy, precise dosing, reduced variability, and dose sparing, which can lead to significant cost savings for consumers. The company has entered into a license agreement with a lead production partner in the United States, enabling the production of nutraceutical products based on or embodying MVMD's proprietary technologies.

Notable proprietary formulation projects include:

1. Opioid Use Disorder (OUD) Adjunct Therapy: MVMD has developed a proprietary OUD formulation using its Quicksome™ technology, which is ready for manufacturing to support anticipated human trials in 2025.
2. Fenugreek Glycosides Testosterone Product: MVMD has formulated a novel sublingual fenugreek glycosides testosterone product with the Quicksome™ technology, currently being tested in male human subjects to promote increased testosterone levels.
3. Circadian Wellness License Agreement and Product Expansion: Under a license agreement with Circadian Wellness Corp., MVMD's Quicksome™ technology is being applied to functional mushroom-based products. Initial product formulation work and dissolution testing have been completed and accepted for Circadian's Eons branded product line, including formulations for sleep, energy, immunity, and anxiety-reducing products.

Agriculture: Agrarius' Organic Approach to Crop Yield Enhancement and Disease Resistance

MVMD's licensed Agrarius agricultural plant signaling technology offers an organic approach to crop yield enhancement and disease resistance. Unlike traditional chemical-based methods, Agrarius activates a plant's "defense mechanisms" at the cellular level without causing stress, leading to increased crop yields, reduced fertilizer usage, and enhanced plant health. The company is currently conducting business development activity in Mexico, Central America, South America, and the United States, recognizing the significant opportunity that Agrarius presents for growth.

Husbandry Animals/Aquatic Species: Quicksol™ Technology for Health Improvement

MVMD's application of solubilized drug formulations through its Quicksol™ technology is designed to positively impact the health of husbandry animals and aquatic species. The company's focus on this area highlights its commitment to supporting the well-being of various species and contributing to sustainable and responsible animal husbandry practices.

In conclusion, Mountain Valley MD's 2024 year-end business update demonstrates the company's significant progress in advancing its commercialization strategies across its three core areas. With its innovative technologies and commitment to global impact, MVMD is well-positioned to continue its growth trajectory and make a meaningful difference in the lives of consumers and the environment. As the company looks ahead to 2025, investors and stakeholders can expect to see further developments and opportunities in the nutraceuticals, agriculture, and husbandry animals/aquatic species sectors.